Flavia Michelini, Director of Translational Medicine (Oncology, ADC), AstraZeneca, shared a post on LinkedIn:
“Excited to share our post hoc analysis from DESTINYPanTumor02: local vs central HER2 IHC concordance and T-DXd efficacy by HER2 IHC status across HER2-expressing solid tumors.
Proud to have contributed to this work.”
Title: Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Authors: Vicky Makker, Jung-Yun Lee, Do-Youn Oh, Ana Oaknin, Soham Puvvada, Lindsey Jung, Robert McEwen, Flavia Michelini, Funda Meric-Bernstam
Other articles about HER2 on OncoDaily.